Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer (PASCART)
|ClinicalTrials.gov Identifier: NCT00724581|
Recruitment Status : Unknown
Verified July 2008 by Aarhus University Hospital.
Recruitment status was: Not yet recruiting
First Posted : July 29, 2008
Last Update Posted : July 29, 2008
Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation.
A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period.
Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population.
Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: Amiodarone||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||275 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial|
|Study Start Date :||August 2008|
|Estimated Primary Completion Date :||August 2009|
|Estimated Study Completion Date :||December 2009|
intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
- Free of atrial fibrillation [ Time Frame: 31082009 ]
- Cost-benefit analysis of amiodarone prophylactic [ Time Frame: 31082009 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00724581
|Contact: Lars R Zebis, MD||+45 email@example.com|
|Contact: Thomas Decker, MD||+45 89495566|
|Aarhus University Hospital, Skejby||Not yet recruiting|
|Aarhus, Denmark, DK-8200|
|Contact: Lars R Zebis, MD, Ph.D. +45 89495566 firstname.lastname@example.org|
|Contact: Thomas D Christensen, MD, Ph.D. +45 89495566|
|Principal Investigator: Lars R Zebis, MD, Ph.D.|
|Principal Investigator:||Lars R Zebis, MD, Ph.D.||Aarhus University Hospital Skejby|